UPC_CFI_40/2025

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Procedural & sub-applicationsCosts AssessmentsHamburg LDGenericCase Closed

Overview Decisions Documents Timeline

Parties

Claimants

Samsung Bioepis NL B.V.

Reps: Elena Hennecke (Freshfields PartG mbB)

Respondents

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Reps: Andrea Ritter (Simmons & Simmons LLP)

Judges

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patents

EP3167888
EP 3 167 888

CPC codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sector: Organic Chemistry

Outcome

Costs only

Filed: Jan 22, 2025

First decided: —

Language: —

Decision of Hamburg Local Division in Samsung Bioepis NL B.V. v Alexion Pharmaceuticals (EP 3 167 888) assessing the costs of appeal proceedings following the Court of Appeal's rejection (20 December 2024) of Alexion's appeal against the dismissal of its application for provisional measures against Samsung Bioepis' Epysqli biosimilar. The court allowed the costs for UPC representatives and patent attorneys but reduced costs claimed for UK solicitors whose involvement (at higher cost than the actual UPC representatives) was not demonstrated to be necessary.

Open on UPC Registry